KMKatherine K. Matthay

Katherine K. Matthay

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katherine K. Matthay has a total of 327 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Circulating Biomarkers of Disease Burden in Patients With Relapsed or Refractory Neuroblastoma Treated With 131 I‐MIBG Therapy: A Report From the New Approaches to Neuroblastoma Therapy Consortium

    by Kevin Campbell, Kelly Klega, Araz Marachelian, Yueh‐Yun Chi, Erica Ma, Anahit Baregamyan, Julie R. Park, Meaghan Granger, Katherine K. Matthay, Shahab Asgharzadeh, et al.

    Background: Circulating tumor DNA (ctDNA) and neuroblastoma‐associated mRNA (NB‐mRNAs) transcripts are detectable in children with neuroblastoma. Less is known about how these biomarkers change during treatment and how they compare to each other. The purpose of this study was to quantify levels of ctDNA and NB‐mRNA before and after 131 I‐metaiodobenzylguanidine therapy ( 131 I‐MIBG). Methods: We utilized peripheral blood and bone marrow samples from NANT11‐01 (NCT02035137), a multicenter, open label, randomized phase II clinical trial evaluating 131 I‐MIBG combinations for patients with relapsed or refractory neuroblastoma. Plasma samples were analyzed for percent ctDNA by ultra‐low passage whole genome sequencing (ULP‐WGS). Blood and bone marrow samples were analyzed for presence of five NB‐mRNAs by a TaqMan low density array (TLDA), called neuroblastoma‐5 (NB5). We evaluated associations between ctDNA and NB5 levels with measures of disease burden and response to therapy using Pearson's correlations and Wilcoxon rank‐sum tests. Results: Samples from 87 patients were evaluated for ctDNA. The proportion of patients with detectable ctDNA decreased from baseline [44% (38/86)] to midcycle 1 [30% (7/23)], to the end of first course [14% (3/21)]. Baseline ctDNA levels correlated positively with total Curie score at baseline ( r = 0.27; p = 0.012) and baseline percent bone marrow involvement ( r = 0.39; p ≤ 0.001). The proportion of patients with positive NB5 in blood was 78% (29/37) at baseline versus 72% (13/18) at End of Course 1. Baseline blood NB5 levels correlated negatively with percent bone marrow involvement ( r = −0.56; p ≤ 0.001) and with sum of target lesions at baseline ( r = −0.4; p = 0.024). Baseline bone marrow NB5 levels correlated negatively with total Curie score at baseline ( r = −0.64; p ≤ 0.001) and percent bone marrow involvement ( r = −0.56; p ≤ 0.001). No marker was significantly associated with objective response. Baseline ctDNA levels were negatively correlated with both blood ( r = −0.79; p < 0.001) and bone marrow ( r = −0.5; p = 0.003) NB5. Conclusions: ctDNA and NB‐mRNA are detectable at multiple time points in patients with relapsed or refractory neuroblastoma treated with 131 I‐MIBG. Both markers correlate with each other and with measures of disease burden, but not with objective response.

  • Factors Impacting Overall Survival Post‐Relapse in High‐Risk Neuroblastoma: Children's Oncology Group Outcomes From 2000 to 2019

    by Monica Davini, Arlene Naranjo, Lulu Chen, Rochelle Bagatell, Steven G. DuBois, Meredith S. Irwin, Kelly C. Goldsmith, Michael D. Hogarty, Katherine K. Matthay

    Purpose: Prior studies of features impacting post‐relapse survival in high‐risk neuroblastoma (HRNB) evaluated patient cohorts that did not receive contemporary high‐risk or relapse therapies. We describe overall survival (OS) after first progression or first relapse of HRNB in a modern cohort. Methods: Patients with HRNB enrolled on COG ANBL00B1(NCT00904241) between 2000 and 2019, who had relapsed or progressive disease were eligible. Clinical and molecular risk factors at diagnosis, therapy era, clinical trial enrollment, and clinical features at relapse, including site of and time to relapse, were evaluated. OS post‐relapse was compared between groups using log‐rank tests and Cox models. Results: Among 4253 eligible HRNB patients, 1616 had relapse or progression as a first event. Five‐year OS post‐relapse was 19.1 ± 1.1%. The risk group with the lowest post‐relapse survival was observed in patients with INSS Stage 4 or 4S disease < 18 months of age at diagnosis with MYCN amplified (MYCN‐A) tumors. The other significant most unfavorable factors at diagnosis included diagnosis 2000–2004, tumor MYCN‐A, 1p loss of heterozygosity (LOH), and elevated LDH or ferritin. Unfavorable factors at relapse included the time to relapse < 36 months from diagnosis, and combined local and metastatic disease at relapse. Multivariable analysis indicated that those with tumors harboring 1p LOH, age ≤ 5 years at diagnosis, or earlier treatment therapy era (2000–2004) had a higher risk of post‐relapse death. Conclusions: While the 5‐year OS rate was low in this cohort, there are subsets of patients with relapsed HRNB who demonstrate long‐term survival. Trials Registration: ClinicalTrials.gov identifier: NCT00904241

  • Open Access

    Clinical and Biological Features of Response in Resistant Neuroblastoma to 131 I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era

    by Benjamin J. Lerman, Katherine K. Matthay, Fabienne Hollinger, Catriona Black, Ann A. Lazar, Miguel Pampaloni, Steven G. DuBois, Kieuhoa T. Vo

    Background: 131 I‐metaiodobenzylguanidine ( 131 I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment. However, response rates to 131 I‐MIBG in the anti‐GD2 era are unknown, and the factors associated with response are poorly defined. Procedure: We retrospectively quantified objective response rates (ORR) to 131 I‐MIBG and evaluated the association between clinical and molecular features—including receipt of anti‐GD2 immunotherapy—and ORR among participants with R/R NB from 2011 to 2023. Variables with an unadjusted odds ratio [uOR] p  < 0.2 in a univariable screen were included in multivariable analysis. Results: A total of 125 participants with relapsed (60.8%) or refractory (39.2%) NB were included. Fifty‐eight (46.4%) previously received anti‐GD2 antibody therapy. Forty‐seven (37.6%) achieved an objective response to 131 I‐MIBG therapy, 56 had stable disease (SD; 44.8%), and 22 had progressive disease (17.6%). Compared to immunotherapy‐naïve participants (ORR 35.8%), participants who previously received anti‐GD2 therapy (39.7%, uOR 1.18 [0.57–2.4]) and specifically chemoimmunotherapy (37.5%, 0.99 [0.42–2.26]) had similar rates of response to 131 I‐MIBG. Asians compared to Whites (adjusted OR 0.21 [0.05–0.95]), no bone marrow disease (0.17 [0.06–0.50]), and higher Curie score (0.90 [0.83–0.98]) were significantly associated with lower odds of response. Conclusion: Prior exposure to anti‐GD2 therapy was not associated with differential response to 131 I‐MIBG. ORR in this modern cohort was comparable to that reported in previous studies. Participants with bone marrow disease and a lower Curie score have a significantly higher ORR to 131 I‐MIBG therapy.

  • Adaptive Clinical Neuroblastoma Risk Groups—Tailoring Treatment in Low- and Middle-Income Countries: An International Neuroblastoma Risk Group Project

    by Wendy B. London, Gabriela Villanueva, Derek Shyr, Jaques van Heerden, Soad Fuentes-Alabi, Raya Saab, Derek Harrison, Ruzanna Papyan, Hoa Thi Kim Nguyen, Dolly Noun, et al.

    PURPOSE: Risk/treatment stratification for children with neuroblastoma (NB) relies on clinical, histologic, and genomic factors. However, most children with cancer live in low- and middle-income countries (LMIC), where access to advanced methods for stratification is limited. To address this unmet need, we developed a novel risk/treatment classification, the Adaptive Clinical Neuroblastoma Risk Groups (ACNRG) using clinical prognostic biomarkers. PATIENTS AND METHODS: A survival tree regression analysis of the International Neuroblastoma Risk Group (INRG) Data Commons (N = 14,501, diagnosed 1990-2014) was performed using univariate Cox regression models (age, International Neuroblastoma Staging System, serum lactate dehydrogenase [LDH], and serum ferritin) of event-free survival (EFS), separately for test and validation sets. Within each terminal node of the survival tree, the proportion of patients by initial treatment assignment and outcome achieved on that treatment were used to subjectively assign risk/treatment intensity (low-, intermediate-, and high-risk). For additional validation, the ACNRG was descriptively compared with INRG classification. Guidelines were developed for determining INRGs Staging System (INRGSS) in LMIC, using the minimum essential versus optimal imaging/biopsy procedures. RESULTS: Twelve statistically, clinically significant unique pretreatment risk groups of INRGSS/age/LDH/ferritin were identified (5-year EFS): low—L1/any/any/any (92% ± 0.5%); intermediate—L2/<18 months/<1,400/any (88% ± 1%), MS/any/<1,400/any (86% ± 1.5%), M/<12 months/<1,400/any (76% ± 2.3%); intermediate/high—L2/<18 months/≥1,400/any (73% ± 4.7%), L2/≥18 months/<1,400/<30 (68% ± 3.4%), L2/≥18 months/<1,400/≥30 (59% ± 3.7%), MS/any/≥1,400/any (52% ± 6.3%); high—L2/≥18 months/≥1,400/any (46% ± 4.7%), M/12-18 months/<1,400/any (64% ± 4.1%), M/<18 months/≥1,400/any (60% ± 1.6%), M/≥18 months/any/any (28% ± 0.8%). The concordance and discordance rates of ACNRG versus INRG were 86.6% and 13.4%, respectively (n = 8,152 nonmissing-data intersection). CONCLUSION: The ACNRG classification, using easily obtained clinical markers, is highly prognostic. The ACNRG could transform risk and treatment stratification, improve accuracy of treatment intensity decisions, and potentially improve outcome, for the large number of children with NB in LMIC. Prospective validation of the ACNRG classification is planned in a pilot trial.


  • Open Access

    International neuroblastoma risk group consortium: a model of networking for rare cancers

    by Susan L Cohn, Wendy B London, Gudrun Schleiermacher, Lucas Moreno, Inge M Ambros, Peter F Ambros, Rochelle Bagatell, Maja Beck Popovic, Klaus Hermann Beiske, Frank Berthold, et al.

    It is critical to share knowledge and harmonize approaches to optimize progress in rare cancers. The International Neuroblastoma Risk Group (INRG) Task Force was formed by the 4 major neuroblastoma cooperative groups in 2004 to achieve this goal. Strategies developed for neuroblastoma are an exemplar for other rare malignancies. Data from an initial cohort of 8800 patients were transferred to the INRG Data Commons, and a data-sharing model was developed. Currently, information on more than 25 000 patients is available to the research community. The INRG staging and risk classification systems have led to harmonized approaches for therapeutic groupings. INRG consensus manuscripts have led to uniform criteria for classifying biological data, evaluating the extent of disease, and defining treatment response. More than 40 INRG research studies have been performed by investigators from around the world, including analyses of rare patients, which would not otherwise be possible. The success of this approach for neuroblastoma has been leveraged to create the Pediatric Cancer Data Commons and the Data for the Common Good. Efforts to enrich the INRG Commons with additional genomic and biomarker data, extracted electronic health records, and digital medical images are ongoing. The international networking model developed by the INRG Task Force has led to new research discoveries and progress in neuroblastoma. The approach has now been applied to 16 other cancers and conditions, including rhabdomyosarcoma, germ cell tumor, Lynch syndrome, and cancer predisposition. This framework of international collaboration and data sharing serves as a model for advancing rare adult malignancies.


  • Phase I Study of 131 I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

    by Thomas Cash, Araz Marachelian, Steven G. DuBois, Yueh-Yun Chi, Anahit Baregamyan, Susan G. Groshen, Hunter C. Jonus, Anasheh Shamirian, Mary Crowley, Fariba Goodarzian, et al.

    PURPOSE: We conducted a phase I trial to determine the safety, tolerability, and preliminary antitumor activity of 131 I-metaiodobenzylguanidine (MIBG) combined with the anti-GD2 antibody dinutuximab with or without the histone deacetylase inhibitor vorinostat in patients with relapsed/refractory neuroblastoma (rNBL). METHODS: In part A, patients with MIBG-avid rNBL received MIBG intravenously (IV) on day 1 at 12, 15, or 18 mCi/kg per the rolling six design and dinutuximab (17.5 mg/m 2 once daily) IV on days 8-11 and 29-32 and granulocyte-macrophage colony-stimulating factor (250 mcg/m 2 once daily) subcutaneously on days 8-17 and 29-38. Autologous stem cells were infused on day 15. In part B, vorinostat at 180 mg/m 2 once daily was given orally on days 0-13 in combination with the part A recommended phase II dose (RP2D). Patients could receive two courses. RESULTS: Forty-five eligible patients enrolled, of whom 31 were evaluable. The median age was 7.5 (range, 2.9-24.1) years. For part A (n = 19), no dose-limiting toxicities (DLTs) occurred across all dose levels and courses, establishing the RP2D of MIBG to be 18 mCi/kg. In part B (n = 12), 1 DLT (grade 3 hypokalemia) occurred during course 1, and 3 of 11 patients who received a second course experienced DLT: grade 3 ALT increase, grade 4 hypoxia and grade 5 pneumonitis, and grade 3 fatigue. The best overall response rate (BORR; complete response [CR] + partial response [PR]) on part A was 42% with a CR/PR/minor response (MR) rate of 46%, and 19% progressive disease (PD) rate. For part B, the BORR was 42% with a CR/PR/MR rate of 75% and 0% PD rate. CONCLUSION: MIBG combined with dinutuximab was well tolerated with encouraging antitumor activity. Vorinostat added to this combination may augment responses in this heavily pretreated patient population.


  • Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531

    by Erin K. Barr, Arlene Naranjo, Clare J. Twist, Sheena C. Tenney, Mary Lou Schmidt, Wendy B. London, Julie Gastier‐Foster, E. Stanton Adkins, Peter Mattei, Michael H. Handler, et al.

    Background: We previously reported excellent three‐year overall survival (OS) for patients with newly diagnosed intermediate‐risk neuroblastoma treated with a biology‐ and response‐based algorithm on the Children's Oncology Group study ANBL0531. We now present the long‐term follow‐up results. Methods: All patients who met the age, stage, and tumor biology criteria for intermediate‐risk neuroblastoma were eligible. Treatment was based on prognostic biomarkers and overall response. Event‐free survival (EFS) and OS were estimated by the Kaplan‐Meier method. Results: The 10‐year EFS and OS for the entire study cohort ( n = 404) were 82.0% (95% confidence interval (CI), 77.2%‐86.9%) and 94.7% (95% CI, 91.8%‐97.5%), respectively. International Neuroblastoma Staging System stage 4 patients ( n = 133) had inferior OS compared with non–stage 4 patients ( n = 271; 10‐year OS: 90.8% [95% CI, 84.5%‐97.0%] vs 96.6% [95% CI, 93.9%‐99.4%], p = .02). Infants with stage 4 tumors with ≥1 unfavorable biological feature ( n = 47) had inferior EFS compared with those with favorable biology ( n = 61; 10‐year EFS: 66.8% [95% CI, 50.4%‐83.3%] vs 86.9% [95% CI, 76.0%‐97.8%], p = .02); OS did not differ (10‐year OS: 84.4% [95% CI, 71.8%‐97.0%] vs 95.0% [95% CI, 87.7%‐100.0%], p = .08). Inferior EFS but not OS was observed among patients with tumors with ( n = 26) versus without ( n = 314) 11q loss of heterozygosity (10‐year EFS: 68.4% [95% CI, 44.5%‐92.2%] vs 83.9% [95% CI, 78.7%‐89.2%], p = .03; 10‐year OS: 88.0% [95% CI, 72.0%‐100.0%] vs 95.7% [95% CI, 92.8%‐98.6%], p = .09). Conclusions: The ANBL0531 trial treatment algorithm resulted in excellent long‐term survival. More effective treatments are needed for subsets of patients with unfavorable biology tumors.


  • Open Access

    Late cognitive and adaptive outcomes of patients with neuroblastoma‐associated opsoclonus‐myoclonus‐ataxia‐syndrome: A report from the Children's Oncology Group

    by Prerna Kumar, Victoria W. Willard, Leanne Embry, Arlene Naranjo, Brian LaBarre, Katherine K. Matthay, Pedro A. de Alarcon

    Background: Opsoclonus‐myoclonus‐ataxia syndrome (OMAS) is a rare autoimmune disorder of the nervous system presenting with abnormal eye and limb movements, altered gait, and increased irritability. Two to four percent of children diagnosed with neuroblastoma have neuroblastoma‐associated OMAS (NA‐OMAS). These children typically present with non‐high‐risk neuroblastoma that is cured with surgery, with or without chemotherapy. Despite excellent overall survival, patients with NA‐OMAS can have significant persistent neurological and developmental issues. Objective: This study aimed to describe long‐term neurocognitive and adaptive functioning of patients with NA‐OMAS treated with multimodal therapy, including intravenous immunoglobulin (IVIG) on Children's Oncology Group (COG) protocol ANBL00P3. Methods: Of 53 children enrolled on ANBL00P3, 25 submitted evaluable neurocognitive data at diagnosis and at least one additional time point within 2 years and were included in the analyses. Adaptive development was assessed via the Vineland Adaptive Behavior Scale, and validated, age‐appropriate measures of intellectual function were also administered. Results: Twenty‐one of the 25 patients in this cohort ultimately received IVIG. Descriptive spaghetti plots suggest that this cohort demonstrated stable long‐term cognitive functioning and adaptive development over time. This cohort also demonstrated decreased OMAS scores over time consistent with improved OMAS symptoms. Conclusions: While statistical significance is limited by small sample size and loss to follow‐up over 10 years, findings suggest stable long‐term cognitive and adaptive functioning over time in this treated cohort.


  • Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131I‐MIBG in patients with relapsed/refractory neuroblastoma

    by Vandana Batra, Ajami Gikandi, Bruce Pawel, Daniel Martinez, M. Meaghan Granger, Araz Marachelian, Julie R. Park, John M. Maris, Kieuhoa T. Vo, Katherine K. Matthay, et al.

    Background: Prior studies suggest that norepinephrine transporter (NET) and vesicular monoamine transporter 2 (VMAT2) mediate meta‐iodobenzylguanidine (MIBG) uptake and retention in neuroblastoma tumors. We evaluated the relationship between NET and VMAT2 tumor expression and clinical response to 131I‐MIBG therapy in patients with neuroblastoma.Methods: Immunohistochemistry (IHC) was used to evaluate NET and VMAT2 protein expression levels on archival tumor samples (obtained at diagnosis or relapse) from patients with relapsed or refractory neuroblastoma treated with 131I‐MIBG. A composite protein expression H‐score was determined by multiplying a semi‐quantitative intensity value (0–3+) by the percentage of tumor cells expressing the protein.Results: Tumor samples and clinical data were available for 106 patients, of whom 28.3% had partial response (PR) or higher. NET H‐score was not significantly associated with response (≥PR), though the percentage of tumor cells expressing NET was lower among responders (median 80% for ≥PR vs. 90% for p = .0014). VMAT2 H‐score was not significantly associated with PR or higher versus less than PR, though patients with PR or higher had lower VMAT2 staining intensity (p = .005). VMAT2 H‐score was significantly lower in patients with complete response (median 40 vs. 210 for patients with p = .0049). VMAT2 H‐scores were significantly higher in ganglioneuroblastoma (vs. neuroblastoma; p = .037), differentiated/poorly differentiated tumors (vs. undifferentiated; p = .0047), and tumors lacking MYCN amplification (vs. MYCN amplified; p = .0011).Conclusions: Markers of lower NET and VMAT2 protein expression are associated with higher likelihood of response to 131I‐MIBG therapy in patients with relapsed/refractory neuroblastoma. Increased VMAT2 protein expression is associated with a more differentiated disease phenotype.


  • Open Access

    Impact of diagnostic and end‐of‐induction Curie scores with tandem high‐dose chemotherapy and autologous transplants for metastatic high‐risk neuroblastoma: A report from the Children's Oncology Group

    by Keri A. Streby, Marguerite T. Parisi, Barry L. Shulkin, Brian LaBarre, Rochelle Bagatell, Lisa Diller, Stephan A. Grupp, Katherine K. Matthay, Stephan D. Voss, Alice L. Yu, et al.

    Background: Diagnostic mIBG (meta‐iodobenzylguanidine) scans are an integral component of response assessment in children with high‐risk neuroblastoma. The role of end‐of‐induction (EOI) Curie scores (CS) was previously described in patients undergoing a single course of high‐dose chemotherapy (HDC) and autologous hematopoietic cell transplant (AHCT) as consolidation therapy.Objective: We now examine the prognostic significance of CS in patients randomized to tandem HDC and AHCT on the Children's Oncology Group (COG) trial ANBL0532.Study design: A retrospective analysis of mIBG scans obtained from patients enrolled in COG ANBL0532 was performed. Evaluable patients had mIBG‐avid, International Neuroblastoma Staging System (INSS) stage 4 disease, did not progress during induction therapy, consented to consolidation randomization, and received either single or tandem HDC (n = 80). Optimal CS cut points maximized the outcome difference (≤CS vs. >CS cut‐off) according to the Youden index.Results: For recipients of tandem HDC, the optimal cut point at diagnosis was CS = 12, with superior event‐free survival (EFS) from study enrollment for patients with CS ≤ 12 (3‐year EFS 74.2% ± 7.9%) versus CS > 12 (59.2% ± 7.1%) (p = .002). At EOI, the optimal cut point was CS = 0, with superior EOI EFS for patients with CS = 0 (72.9% ± 6.4%) versus CS > 0 (46.5% ± 9.1%) (p = .002).Conclusion: In the setting of tandem transplantation for children with high‐risk neuroblastoma, CS at diagnosis and EOI may identify a more favorable patient group. Patients treated with tandem HDC who exhibited a CS ≤ 12 at diagnosis or CS = 0 at EOI had superior EFS compared to those with CS above these cut points.